Kyverna Therapeutics (KYTX) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for Kyverna Therapeutics (KYTX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||
Research And Development | 30M (+0.20%) | 30M (-1.48%) | 30M (-14.96%) | 36M (-4.30%) | 37M (+11.80%) | 33M (+14.70%) | 29M (+6.84%) | 27M (+21.53%) | 22M (+31.00%) | 17M (+25.81%) | 14M (+31.03%) | 10M (+19.52%) | 8.71M |
Selling General And Administrative | 11M (+21.79%) | 9.27M (+12.09%) | 8.27M (-3.73%) | 8.59M (-13.93%) | 9.98M (+32.01%) | 7.56M (-21.09%) | 9.58M (+56.79%) | 6.11M (-11.19%) | 6.88M (+63.42%) | 4.21M (+59.47%) | 2.64M (-8.97%) | 2.90M (+6.23%) | 2.73M |
Operating Expenses | 41M (+5.32%) | 39M (+1.42%) | 39M (-12.79%) | 44M (-6.33%) | 47M (+15.52%) | 41M (+5.86%) | 39M (+15.94%) | 33M (+13.90%) | 29M (+37.32%) | 21M (+31.33%) | 16M (+22.41%) | 13M (+16.16%) | 11M |
Depreciation And Amortization | 350K (-50.00%) | 700K (+133.33%) | 300K (0.00%) | 300K (-40.00%) | 500K (-52.38%) | 1.05M (+250.00%) | 300K (0.00%) | 300K (-37.50%) | 480K (-47.25%) | 910K (+355.00%) | 200K (0.00%) | 200K (-48.72%) | 390K |
Operating Income | |||||||||||||
Operating Income | -41.37M (+5.32%) | -39.28M (+1.42%) | -38.73M (-12.79%) | -44.41M (-6.33%) | -47.41M (+15.52%) | -41.04M (+5.86%) | -38.77M (+15.97%) | -33.43M (+13.86%) | -29.36M (+37.32%) | -21.38M (+31.33%) | -16.28M (+22.41%) | -13.30M (+16.26%) | -11.44M |
Ebit | -41.37M (+5.32%) | -39.28M (+1.42%) | -38.73M (-12.79%) | -44.41M (-6.33%) | -47.41M (+15.52%) | -41.04M (+5.86%) | -38.77M (+15.97%) | -33.43M (+13.86%) | -29.36M (+37.32%) | -21.38M (+31.33%) | -16.28M (+22.41%) | -13.30M (+16.26%) | -11.44M |
EBITDA | -41.02M (+6.32%) | -38.58M (+0.39%) | -38.43M (-12.88%) | -44.11M (-5.97%) | -46.91M (+17.30%) | -39.99M (+3.95%) | -38.47M (+16.12%) | -33.13M (+14.72%) | -28.88M (+41.15%) | -20.46M (+27.24%) | -16.08M (+22.75%) | -13.10M (+18.55%) | -11.05M |
Other Income / Expenses | |||||||||||||
Interest Income | 2.33M (+21.99%) | 1.91M (-4.50%) | 2.00M (-15.25%) | 2.36M (-16.61%) | 2.83M (-20.95%) | 3.58M (-17.89%) | 4.36M (-7.04%) | 4.69M (+71.17%) | 2.74M (+246.84%) | 790K (-10.23%) | 880K (+238.46%) | 260K (-25.71%) | 350K |
Interest Expense | 670K (+52.27%) | 440K (+4300.00%) | 10K (0.00%) | 10K (-66.67%) | 30K (0.00%) | 30K (0.00%) | 30K (-25.00%) | 40K (0.00%) | 40K (-20.00%) | 50K (0.00%) | 50K (0.00%) | 50K (+25.00%) | 40K |
Net Interest Income | 2.33M (+21.99%) | 1.91M (-4.50%) | 2.00M (-15.25%) | 2.36M (-16.61%) | 2.83M (-22.68%) | 3.66M (-16.06%) | 4.36M (-6.44%) | 4.66M (+73.23%) | 2.69M (+205.68%) | 880K (0.00%) | 880K (+300.00%) | 220K (-29.03%) | 310K |
Other Non Operating Income | -20.00K (-75.00%) | -80.00K (+60.00%) | -50.00K (+150.00%) | -20.00K (-33.33%) | -30.00K (-66.67%) | -90.00K (+125.00%) | -40.00K (+100.00%) | -20.00K (-33.33%) | -30.00K (-40.00%) | -50.00K (+400.00%) | -10.00K (0.00%) | -10.00K | - |
Net Income | |||||||||||||
Net Income From Continuing Operations | -39.73M (+5.11%) | -37.80M (+2.75%) | -36.79M (-12.57%) | -42.08M (-5.71%) | -44.63M (+19.05%) | -37.49M (+8.70%) | -34.49M (+19.76%) | -28.80M (+7.91%) | -26.69M (+29.12%) | -20.67M (+33.70%) | -15.46M (+18.11%) | -13.09M (+17.50%) | -11.14M |
Net Income | -39.73M (+5.11%) | -37.80M (+2.75%) | -36.79M (-12.57%) | -42.08M (-5.71%) | -44.63M (+19.05%) | -37.49M (+8.70%) | -34.49M (+19.76%) | -28.80M (+7.91%) | -26.69M (+29.12%) | -20.67M (+33.70%) | -15.46M (+18.11%) | -13.09M (+17.50%) | -11.14M |
Comprehensive Income Net Of Tax | -39.92M (-75.25%) | -161.31M (+339.06%) | -36.74M (-12.73%) | -42.10M (-5.90%) | -44.74M (-64.88%) | -127.38M (+271.37%) | -34.30M (+18.93%) | -28.84M (+8.01%) | -26.70M (-55.75%) | -60.34M (+290.30%) | -15.46M (+18.20%) | -13.08M (+17.63%) | -11.12M |